MX2008012015A - Formas cristalinas de sales de n-{2-tert-butil-1-[(4,4-difluorocic lohexil)metil]-1h-bencimidazol-5-il}etanosulfonamida. - Google Patents
Formas cristalinas de sales de n-{2-tert-butil-1-[(4,4-difluorocic lohexil)metil]-1h-bencimidazol-5-il}etanosulfonamida.Info
- Publication number
- MX2008012015A MX2008012015A MX2008012015A MX2008012015A MX2008012015A MX 2008012015 A MX2008012015 A MX 2008012015A MX 2008012015 A MX2008012015 A MX 2008012015A MX 2008012015 A MX2008012015 A MX 2008012015A MX 2008012015 A MX2008012015 A MX 2008012015A
- Authority
- MX
- Mexico
- Prior art keywords
- acid salt
- ethanesulfonamide
- benzimidazol
- tert
- butyl
- Prior art date
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title abstract 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 4,4-difluorocyclohexyl Chemical group 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 1
- 125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical class OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 abstract 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 abstract 1
- 150000002688 maleic acid derivatives Chemical class 0.000 abstract 1
- 150000003016 phosphoric acids Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003892 tartrate salts Chemical class 0.000 abstract 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con nuevas sales de N-{2-tert-butil-1-[(4,4-difluorociclohexil)metil]-1H-bencimidazol -5-il}etanosulfonamida, cuyo compuesto tiene la siguiente fórmula (ver fórmula): Este compuesto es útil como un ligando del receptor CB1, y puede ser útil en el tratamiento del dolor y/o de otras enfermedades o síntomas relacionados. La invención también se refiere a las composiciones farmacéuticas que incluyen las sales, así como los procesos para la fabricación de las sales. La invención además se refiere a los métodos de tratamiento de condiciones médicas en las cuales los receptores CB1 están implicados usando sales, por ejemplo dolor, trastornos de ansiedad, cáncer, esclerosis múltiple, enfermedad de Parkinson, corea de Hunt Alsheimer, trastornos gastrointestinales cardiovasculares, y el uso de las sales en la fabricación de un medicamento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78532606P | 2006-03-23 | 2006-03-23 | |
| PCT/SE2007/000281 WO2007108754A1 (en) | 2006-03-23 | 2007-03-22 | Crystalline forms of n- {2-tert -butyl -1- [ (4,4- dif luorocyclohexyl) methyl] -lh-benzimidazol-5- yl}ethanesulfonamide salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008012015A true MX2008012015A (es) | 2008-10-01 |
Family
ID=38522716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008012015A MX2008012015A (es) | 2006-03-23 | 2007-03-22 | Formas cristalinas de sales de n-{2-tert-butil-1-[(4,4-difluorocic lohexil)metil]-1h-bencimidazol-5-il}etanosulfonamida. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7566788B2 (es) |
| EP (1) | EP2001856A4 (es) |
| JP (1) | JP2009530373A (es) |
| KR (1) | KR20080105098A (es) |
| CN (1) | CN101454293A (es) |
| AR (1) | AR060065A1 (es) |
| AU (1) | AU2007227811A1 (es) |
| BR (1) | BRPI0709631A2 (es) |
| CA (1) | CA2648829A1 (es) |
| EC (1) | ECSP088714A (es) |
| IL (1) | IL193671A0 (es) |
| MX (1) | MX2008012015A (es) |
| NO (1) | NO20084353L (es) |
| RU (1) | RU2008136556A (es) |
| TW (1) | TW200745049A (es) |
| UY (1) | UY30232A1 (es) |
| WO (1) | WO2007108754A1 (es) |
| ZA (1) | ZA200807598B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0302573D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| MX2007003105A (es) | 2004-09-24 | 2007-06-07 | Aztrazeneca Ab | Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i. |
| TW200808769A (en) | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
| US20110086853A1 (en) * | 2009-10-08 | 2011-04-14 | William Brown | Therapeutic Compounds |
| CN101758337B (zh) * | 2009-12-03 | 2012-02-15 | 湖南阿斯达生化科技有限公司 | 一种助焊剂用非卤素活性剂 |
| GB202019335D0 (en) * | 2020-12-08 | 2021-01-20 | Artelo Biosciences Ltd | Pharmaceutical compositions |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1604908A (en) | 1965-06-24 | 1971-05-15 | Substd benzimidazoles - with anthelmintic,fungicidal activity and some with antiviral and antibacterial activity | |
| FR5354M (es) | 1965-09-10 | 1967-09-11 | ||
| US5387600A (en) | 1992-07-30 | 1995-02-07 | Fuji Photo Film Co., Ltd. | Treating arteriosclerosis using benzimidazole compositions |
| DE4237557A1 (de) | 1992-11-06 | 1994-05-11 | Bayer Ag | Substituierte Benzimidazole |
| DE4237617A1 (de) * | 1992-11-06 | 1994-05-11 | Bayer Ag | Verwendung von substituierten Benzimidazolen |
| DE4237597A1 (de) | 1992-11-06 | 1994-05-11 | Bayer Ag | Substituierte Benzimidazole |
| AU722514B2 (en) | 1995-12-28 | 2000-08-03 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| US6348032B1 (en) * | 1998-11-23 | 2002-02-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with benzimidazole derivatives |
| AU6762400A (en) | 1999-08-12 | 2001-03-13 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
| US6844367B1 (en) * | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| US6720317B1 (en) * | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| JP2003509412A (ja) | 1999-09-17 | 2003-03-11 | シーオーアール セラピューティクス インコーポレイテッド | Ｘａ因子阻害剤 |
| US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| SK287527B6 (sk) | 2000-01-14 | 2011-01-04 | Bayer Schering Pharma Aktiengesellschaft | 1,2-Diarylbenzimidazoly a ich farmaceutické použitie |
| US7115645B2 (en) * | 2000-01-14 | 2006-10-03 | Schering Aktiengesellschaft | 1,2 diarylbenzimidazoles and their pharmaceutical use |
| AU2001250783A1 (en) * | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| US20070004713A1 (en) | 2000-12-07 | 2007-01-04 | Bernard Barlaam | Therapeutic benimidazole compounds |
| SE0101387D0 (sv) * | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | Novel compounds |
| JPWO2002100833A1 (ja) | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Ｒｈｏキナーゼ阻害剤 |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| SE0301699D0 (sv) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0301701D0 (sv) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| US20050026968A1 (en) | 2003-07-14 | 2005-02-03 | University Of Tennessee Research Foundation | Heterocyclic amides with anti-tuberculosis activity |
| WO2005021547A2 (en) | 2003-08-28 | 2005-03-10 | Pharmaxis Pty Ltd. | Heterocyclic cannabinoid cb2 receptor antagonists |
| SE0302570D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0302572D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0302571D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0302573D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| CA2567343A1 (en) | 2004-05-20 | 2005-12-01 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| EP1765332A2 (en) | 2004-06-17 | 2007-03-28 | Cengent Therapeutics, Inc. | Trisubstituted nitrogen modulators of tyrosine phosphatases |
| SG155188A1 (en) | 2004-07-30 | 2009-09-30 | Exelixis Inc | Pyrrole derivatives as pharmaceutical agents |
| US20060052421A1 (en) * | 2004-09-09 | 2006-03-09 | Eastman Kodak Company | Conjugation agent |
| EP1797076A1 (en) | 2004-09-24 | 2007-06-20 | AstraZeneca AB | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| EP1797070A1 (en) | 2004-09-24 | 2007-06-20 | AstraZeneca AB | Compounds, compositions containing them, preparations thereof and uses thereof ii |
| MX2007003105A (es) * | 2004-09-24 | 2007-06-07 | Aztrazeneca Ab | Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i. |
| WO2006033630A1 (en) | 2004-09-24 | 2006-03-30 | Astrazeneca Ab | Compounds, compositions containing them, preparation thereof and uses thereof iii |
| WO2006033629A1 (en) | 2004-09-24 | 2006-03-30 | Astrazeneca Ab | Benzimidazole derivatives and their use as cannabinoid receptor ligands |
| WO2006033631A1 (en) | 2004-09-24 | 2006-03-30 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i |
| WO2006033627A1 (en) | 2004-09-24 | 2006-03-30 | Astrazeneca Ab | Compounds, compositions containing them, preparation thereof and uses thereof iiii |
| WO2006033632A1 (en) | 2004-09-24 | 2006-03-30 | Astrazeneca Ab | Benzimidazole derivatives and their use as cannabinoid receptor ligands I |
| MX2007005290A (es) * | 2004-11-02 | 2007-07-09 | Pfizer | Derivados de sulfonilbencimidazol. |
| WO2006078941A2 (en) | 2005-01-20 | 2006-07-27 | Sirtris Pharmaceuticals, Inc. | Novel sirtuin activating compounds and methods of use thereof |
-
2007
- 2007-03-20 TW TW096109540A patent/TW200745049A/zh unknown
- 2007-03-22 UY UY30232A patent/UY30232A1/es unknown
- 2007-03-22 US US11/689,864 patent/US7566788B2/en not_active Expired - Fee Related
- 2007-03-22 EP EP07716083A patent/EP2001856A4/en not_active Withdrawn
- 2007-03-22 AR ARP070101183A patent/AR060065A1/es unknown
- 2007-03-22 MX MX2008012015A patent/MX2008012015A/es not_active Application Discontinuation
- 2007-03-22 AU AU2007227811A patent/AU2007227811A1/en not_active Abandoned
- 2007-03-22 JP JP2009501381A patent/JP2009530373A/ja active Pending
- 2007-03-22 WO PCT/SE2007/000281 patent/WO2007108754A1/en not_active Ceased
- 2007-03-22 KR KR1020087023039A patent/KR20080105098A/ko not_active Withdrawn
- 2007-03-22 RU RU2008136556/04A patent/RU2008136556A/ru not_active Application Discontinuation
- 2007-03-22 BR BRPI0709631-3A patent/BRPI0709631A2/pt not_active Application Discontinuation
- 2007-03-22 CN CNA2007800189539A patent/CN101454293A/zh active Pending
- 2007-03-22 CA CA002648829A patent/CA2648829A1/en not_active Abandoned
-
2008
- 2008-08-25 IL IL193671A patent/IL193671A0/en unknown
- 2008-09-03 ZA ZA200807598A patent/ZA200807598B/xx unknown
- 2008-09-03 EC EC2008008714A patent/ECSP088714A/es unknown
- 2008-10-16 NO NO20084353A patent/NO20084353L/no not_active Application Discontinuation
-
2009
- 2009-07-23 US US12/508,112 patent/US20100022610A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080105098A (ko) | 2008-12-03 |
| US7566788B2 (en) | 2009-07-28 |
| EP2001856A4 (en) | 2011-02-16 |
| US20100022610A1 (en) | 2010-01-28 |
| EP2001856A1 (en) | 2008-12-17 |
| CN101454293A (zh) | 2009-06-10 |
| JP2009530373A (ja) | 2009-08-27 |
| NO20084353L (no) | 2008-10-16 |
| UY30232A1 (es) | 2007-10-31 |
| ZA200807598B (en) | 2010-02-24 |
| ECSP088714A (es) | 2008-10-31 |
| US20070225346A1 (en) | 2007-09-27 |
| RU2008136556A (ru) | 2010-04-27 |
| IL193671A0 (en) | 2009-05-04 |
| AR060065A1 (es) | 2008-05-21 |
| WO2007108754A1 (en) | 2007-09-27 |
| AU2007227811A1 (en) | 2007-09-27 |
| CA2648829A1 (en) | 2007-09-27 |
| TW200745049A (en) | 2007-12-16 |
| BRPI0709631A2 (pt) | 2011-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2008012015A (es) | Formas cristalinas de sales de n-{2-tert-butil-1-[(4,4-difluorocic lohexil)metil]-1h-bencimidazol-5-il}etanosulfonamida. | |
| NO2020042I1 (no) | Entrektinib eller isomerer, tautomerer, eller farmasøytisk akseptable salter derav | |
| AR057056A1 (es) | Proceso para la sintesis de imidazol bencilaminas | |
| CY1109727T1 (el) | Παραγωγα ν3 αλκυλιωμενου βενζιμιδαζολιου ως αναστολεις μεκ | |
| FR18C1028I2 (fr) | Formes cristallines d'un derive d'imidazole | |
| WO2010125216A3 (es) | Preparación de compuestos 5,6-dihidropirido[2,3-d]pirimidin-7(8h)-ona sustituidos | |
| DE60324800D1 (de) | Schwalbenschwanzförmige gewindekupplung für expandierbare rohre | |
| PT2404906E (pt) | Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa | |
| SI2057122T1 (sl) | Derivati 4-(2-amino-1-hidroksietil)fenola kot agonisti beta2-adrenergičnega receptorja | |
| WO2008006043A3 (en) | 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents | |
| WO2008036967A3 (en) | Novel heterocyclic compounds as lasy activators | |
| EA200970372A1 (ru) | Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение | |
| IL181158A0 (en) | Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i?á | |
| MX2010003849A (es) | Antagonistas de cgrp. | |
| ES2421896T3 (es) | Compuestos de aril-(imidazol)-metil-fenilo sustituidos como moduladores selectivos de los subtipos de receptores adrenérgicos alfa 2B y/o alfa 2C | |
| CO5700771A2 (es) | Antagonistas del receptor hidroisoindolina taquiquinina | |
| IL227951A0 (en) | Crystalline and amorphous forms of -5-amino-1-[2,6-dichloro-4-(trifluoromethyl)-4-[(trifluoromethyl)sulfinyl]-1-h-carbonitrile | |
| DK1603917T3 (da) | Immunmodulerende heterocycliske forbindelser | |
| MXPA06000185A (es) | Derivados de quinazolinas 5-sustituidas. | |
| WO2006010969A8 (en) | New heterocyclic carboxylic acid amide derivatives | |
| AR063646A1 (es) | Proceso para la sulfinilacion de un derivado de pirazol | |
| WO2007102074A3 (en) | Salts of quetiapine | |
| EA201400570A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ БЕНЗОТИАЗЕПИНОВ ИЗ γ-АМИНОАЛКИЛБЕНЗОЛОВ | |
| NO20044867L (no) | Nye salter | |
| NO20091491L (no) | Fluorerte catharantinderivater, deres fremstilling og deres anvendelse som vincadimore alkaloidforlopere |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |